In addition, there was no significantly increased risk of NTM in RA patients receiving non-anti-TNF biologics (crude OR = 2.14, 95% CI 0.84–5.41, p = 0.109) compared with non-users. The gene discussed is TNF; the disease is rheumatoid arthritis.